Atagabalin (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name PD-0200390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2).[1][2] It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results.[1][3][4][5][6] The drug reached phase 2clinical trials for this indication prior to the discontinuation of its development.[1]
1234"Atagabalin". AdisInsight. 5 November 2023. Retrieved 3 October 2025.
↑Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins". Bioorganic & Medicinal Chemistry Letters. 20 (2): 461–4. doi:10.1016/j.bmcl.2009.11.118. PMID20005103.
↑Atkin T, Comai S, Gobbi G (April 2018). "Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery". Pharmacol Rev. 70 (2): 197–245. doi:10.1124/pr.117.014381. PMID29487083.
↑Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research. 28 (10): 2610–27. doi:10.1007/s11095-011-0490-x. PMID21681607. S2CID22241527.
